Every 8-K that Tela Bio, Inc. (TELA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TELA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TELA filings page.
TELA Bio, Inc. (TELA) announced a strategic cost reduction plan and leadership changes. The Board approved a reduction in workforce of approximately 20%, cutting full-time employees from 201 to 160, expected to be substantially completed in the third quarter of 2026. The company anticipates a one-time restructuring charge of about $1.5 million, primarily for severance and other employee-related costs, largely resulting in cash outflows in that quarter.
TELA Bio targets an approximately $17.0 million, or 18%, reduction in annual operating expenses through the headcount reduction and streamlining of external resources and expects this initiative to extend its cash runway into 2028. Effective August 31, 2026, Roberto Cuca stepped down as Chief Financial Officer, Chief Operating Officer, Corporate Secretary and principal financial officer, treated as a termination without cause under his employment agreement. The Board appointed Heather Getz as principal financial officer, and the company plans to detail the initiatives further on its Q3 2026 earnings call.
TELA Bio, Inc. amended a prior report to detail the separation agreement with former Chief Executive Officer Antony Koblish, whose role ended on August 3, 2026. As of the August 7, 2026 effective date, Mr. Koblish receives accrued salary through his separation date and eligibility to elect continued health, dental and vision coverage through August 31, 2026.
He is entitled to 12 months of base salary, paid in regular payroll installments, and up to 12 months of COBRA premiums paid by the company if he timely elects coverage. All of his outstanding equity awards immediately vest as of the effective date, and his stock option exercise period is extended until the earlier of December 31, 2027 or each option’s normal expiration, subject to earlier termination on a change in control. His performance stock units may still vest based on revenue and gross margin goals through December 31, 2026, or at target if a change in control occurs by that date. In return, he provides a general release and waiver of claims.
TELA Bio reported second quarter 2026 revenue of $19.3 million, down 4% from $20.2 million a year earlier, as OviTex PRS volumes declined and price/mix pressures in hernia procedures persisted. Gross profit was $13.9 million, with gross margin improving to 72% from 70%, helped by a tariff refund and lower excess and obsolete inventory charges.
Operating expenses held flat at $23.2 million, but net loss widened to $11.3 million from $9.9 million. As of June 30, 2026, cash and cash equivalents were $30.4 million, long-term debt was $56.1 million, and stockholders’ equity shifted to a $15.9 million deficit from positive $6.3 million at year-end 2025. Management withdrew full-year 2026 revenue guidance while the new CEO reviews strategy, citing the need to improve PRS performance, accelerate hernia market share gains, and take decisive actions to extend the cash runway and align costs with the top line. Hernia unit volumes grew 12% year over year, and international revenue continued to increase.
TELA Bio, Inc. made a leadership change on August 3, 2026, when the board determined that Antony Koblish would no longer serve as chief executive officer and principal executive officer and he resigned from the board, with his departure treated as a termination without cause and a separation agreement to be finalized and disclosed later.
The board appointed Heather Getz as chief executive officer, principal executive officer and a Class II director, and entered into an employment agreement providing a $650,000 base salary, a target annual bonus equal to 100% of salary, severance of 12 months salary and benefits if terminated without Cause or for Good Reason, enhanced to 18 months salary, 150% of target bonus and accelerated equity vesting during a Change of Control Period. As inducement equity, she received options for 1,365,000 shares at market price, premium options for 1,005,000 shares at the higher of $0.90 or a 15% premium, and 500,000 RSUs, plus potential top-up grants so that her Initial and Top-Up Grants equal 5% of outstanding shares after future equity financings.
TELA Bio, Inc. reported the results of its 2026 annual stockholder meeting. Stockholders approved an amendment to the Amended and Restated 2019 Equity Incentive Plan that increases the authorized shares issuable under the plan by 3,500,000 shares, expanding the pool available for employee and director equity awards.
Three Class I directors—Joseph Capper, Betty Jo Rocchio and William Plovanic—were re-elected to serve until the 2029 annual meeting. Stockholders also ratified KPMG LLP as independent auditor for the 2026 fiscal year and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. As of April 24, 2026, there were 44,765,928 shares of common stock outstanding.
TELA Bio, Inc. reported first quarter 2026 results showing modest growth while remaining unprofitable. Revenue was $19.1 million, up 3% from the same period in 2025, driven by 13% unit growth and increasing international sales, partially offset by U.S. product mix headwinds from rapid growth of smaller-sized units.
Gross profit was $12.5 million, with a gross margin of 65.7% versus 67.6% a year earlier, mainly due to higher charges for excess and obsolete inventory. Operating expenses held flat at $23.0 million, resulting in a loss from operations of $10.5 million, similar to 2025. Net loss widened slightly to $12.3 million.
Cash and cash equivalents totaled $39.5 million as of March 31, 2026. Management reiterated its 2026 financial guidance and highlighted a fully built commercial organization, early traction in Europe, and the full U.S. commercial launch of OviTex LTR, aimed at supporting more predictable growth through the remainder of 2026.
TELA Bio, Inc. reported preliminary, unaudited revenue of approximately $19.0 million for the quarter ended March 31, 2026. Management prepared this estimate before completing quarter-end closing procedures, and the company’s auditor, KPMG LLP, has not performed any review or assurance work on it. Actual results may differ and will be reflected in the upcoming Form 10‑Q.
The company also announced significant board changes. Chairman Doug Evans and three other directors will retire from the board immediately following the 2026 Annual Meeting, with no departures due to disagreements over operations or policies. The board has nominated Joseph Capper, who is not expected to qualify as independent under Nasdaq rules, to join as a Class I director and become Chairman upon his election. Three new independent directors — Guido Neels, Guy Nohra, and Paul Thomas — will join in different board classes and assume key committee roles after the 2026 Annual Meeting. Subject to their election and appointment, each of these incoming directors and Mr. Capper will receive an initial equity award following the annual meeting, consisting of stock options and restricted stock units that vest over three years.
TELA Bio reported strong revenue growth but continued losses for the fourth quarter and full year 2025. Fourth quarter revenue reached $20.9 million, up 18% from 2024, with gross margin of 65.9% and a reduced operating loss of $6.6 million. Full-year revenue was $80.3 million, a 16% increase, and gross margin improved to 67.7%, while the net loss widened slightly to $38.8 million. Cash and cash equivalents were $50.8 million at December 31, 2025, against long-term debt of $55.7 million. Management highlighted its largest quarterly revenue to date, 88 revenue-generating representatives, and expressed confidence in achieving at least 8% revenue growth in 2026 while progressing toward profitability without raising additional capital.
TELA Bio, Inc. reported that it received a notice from Nasdaq stating its common stock has closed below the required $1.00 per share minimum bid price for 30 consecutive business days, putting the company out of compliance with Nasdaq Listing Rule 5450(a)(1) for the Nasdaq Global Market.
The stock will continue trading under the symbol “TELA” for now, and the notice has no immediate effect on the current listing. TELA Bio has until September 14, 2026 to regain compliance, which would occur if the closing bid price stays at or above $1.00 for at least 10 consecutive business days.
If compliance is not regained by that date, Nasdaq may grant an additional 180-day period if TELA transfers to the Nasdaq Capital Market and meets its other listing standards. Failure to regain compliance after these periods could lead to delisting, though the company would have the right to appeal. TELA Bio plans to monitor its share price and explore options to resolve the deficiency.
TELA Bio entered a senior secured term loan with Perceptive for up to $70.0 million. An initial $60.0 million will fund on November 14, 2025, with an additional $10.0 million delayed draw available subject to conditions. The facility matures on November 14, 2030, bears interest at 7.85% plus the greater of the Reference Rate or 4.25% (minimum 12.10% per annum), has no scheduled amortization, and includes prepayment premiums of 2%–10%. Obligations are secured by a first‑lien on substantially all assets.
As consideration, TELA will issue warrants to purchase up to 2,000,000 shares at $1.11 on closing and up to 333,333 shares at $1.11 if the delayed draw is funded; the warrants expire on November 14, 2035 and permit cashless exercise and resale registration rights. A post‑closing condition requires evidence by November 17, 2025 of at least $8,500,000 in gross proceeds from a registered direct offering.
Separately, TELA launched an underwritten registered direct offering of 4,189,000 shares at $1.11 and 7,523,000 pre‑funded warrants at $1.1099, for expected net proceeds of about $11.9 million. Pre‑funded warrants are immediately exercisable at $0.0001 with a 9.99% (or 4.99%) beneficial ownership cap. The prior MidCap facility was terminated and its lien released.
TELA Bio, Inc. furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025 and updated its corporate slide deck.
The press release is furnished as Exhibit 99.1 and the investor presentation as Exhibit 99.2, each dated November 13, 2025. The materials are furnished, not filed, and are not subject to Section 18 liability, and are incorporated by reference only if specifically referenced in a future filing.
TELA Bio expanded its Board of Directors from six to seven members and appointed William Plovanic as a Class I director, with his term expiring at the 2026 Annual Meeting of Stockholders. The Board determined he is an independent director under Nasdaq rules.
Plovanic, 56, brings experience as Managing Director of Healthcare Equity Research at Canaccord Genuity and prior leadership roles at Obalon Therapeutics. Upon appointment, he received an initial equity award consisting of an option to purchase 17,550 shares vesting in 36 equal monthly installments and 11,925 RSUs vesting in three equal annual installments, granted under the company’s 2019 Equity Incentive Plan. He will receive a $45,000 annual cash retainer for Board service. Beginning at the 2026 Annual Meeting, his annual equity awards will include options for 11,700 shares and 7,950 RSUs, each vesting on the earlier of one year from grant, the next annual meeting, or a change in control, subject to continued service.
TELA Bio reported a change in its board of directors. On October 4, 2025, director Lisa Colleran resigned from the Board and from the Nominating and Corporate Governance and Audit Committees, and her resignation was not due to any disagreement with the company’s operations, policies, or practices.
On October 7, 2025, the Board appointed Dr. Betty Jo Rocchio as a Class I director, effective October 9, 2025, with a term running until the 2026 annual meeting. She is an experienced senior nursing executive and has been deemed an independent director under Nasdaq rules, with no related-party or family relationships disclosed.
In connection with her appointment, Dr. Rocchio received an initial equity package of an option for 17,550 shares and 11,925 restricted stock units, vesting over three years, plus an annual cash retainer of $45,000. Beginning with the 2026 annual meeting, she is eligible for recurring annual equity awards of options for 11,700 shares and 7,950 restricted stock units, subject to continued service.
TELA Bio, Inc. furnished a press release reporting its financial results for the quarter ended June 30, 2025 and provided an updated corporate slide deck for investor meetings. The Form 8-K identifies the relevant disclosure items as Item 2.02 (results of operations and financial condition) and Item 7.01 (Regulation FD disclosure), and lists exhibits including the press release (Exhibit 99.1), the slide deck (Exhibit 99.2) and the Inline XBRL cover page (Exhibit 104). The filing notes these materials are furnished, not filed, and the document is signed by CEO Antony Koblish. The company’s common stock trades on Nasdaq under the symbol TELA and the registrant indicates emerging growth company status.